{ "run": { "id": "cmnr14lng0552p658gprm25ij", "region": "US", "assetId": "cmnr14ln2054yp658qyct35xi", "ticker": "MO", "snapshotId": "cmnr14ln70550p65884zfk0xn", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:24.890Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14ln70550p65884zfk0xn", "assetId": "cmnr14ln2054yp658qyct35xi", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 66.8, "dayLow": 64.36, "volume": 10801740, "dayHigh": 66.855, "currency": "USD", "prevClose": 66.25, "week52Low": 54.7, "week52High": 70.51 }, "fundamentals": { "pe": 13.995145631068, "beta": 0.259206828960229, "epsTTM": 4.12, "fcfTTM": 8931000000, "growth": { "epsYoy": -0.3700305810397553, "revenueYoy": -0.03076859022399867 }, "sector": "Cigarettes", "margins": { "net": 0.2984234717986168, "gross": 0.6246831908587138, "operating": 0.4252330426564715 }, "website": "https://www.altria.com/", "industry": "Tobacco", "pegRatio": -0.378215919120597, "ebitdaTTM": 10085000000, "forwardPe": 10.2964285714286, "marketCap": 98000000000, "totalCash": 4474000000, "totalDebt": 25709000000, "debtEquity": -7.34123358081097, "quickRatio": 0.5174786978370112, "revenueTTM": 23279000000, "companyName": "ALTRIA GROUP, INC.", "priceToBook": -28.1117555040556, "currentRatio": 0.6480227223071882, "dividendYield": 0.0722472320684967, "returnOnAssets": 0.1983893537424679, "returnOnEquity": -1.98372358652199, "analystOpinions": null, "businessSummary": "Altria Group, Inc. is an American corporation and one of the world's largest producers and marketers of tobacco, cigarettes, and medical products in the treatment of illnesses caused by tobacco. It operates worldwide and is headquartered in the city of Richmond, Virginia.", "enterpriseValue": 118276780000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 5900, "sharesOutstanding": 1671898087, "enterpriseToEbitda": 11.72799008428359, "analystTargetMedian": null, "enterpriseToRevenue": 5.080835946561279, "operatingCashflowTTM": 9290000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:24.883Z" }, "results": [ { "id": "cmnr14lnj0554p658jj1fb25l", "runId": "cmnr14lng0552p658gprm25ij", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MO\",\"currency\":\"USD\",\"current_price\":66.8,\"target_price_6m\":70.5,\"target_price_12m\":73.0,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"~7.2% dividend yield provides strong downside support and total return floor\",\"Forward P/E of ~10.3x implies normalized EPS well above depressed TTM figure\",\"Pricing power consistently offsets mid-single-digit cigarette volume declines\",\"NJOY acquisition positions Altria in growing reduced-risk product category\",\"Massive FCF (~$8.9B TTM) funds dividends, buybacks, and debt reduction\"],\"key_drivers\":[{\"driver\":\"Cigarette pricing power offsetting volume declines\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"NJOY and smoke-free product portfolio growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Secular decline in combustible cigarette volumes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Share repurchase program reducing share count\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High dividend yield attracting income-focused capital\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FDA regulatory actions on menthol and nicotine levels\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated leverage with negative book equity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta providing portfolio defensiveness\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Potential excise tax increases\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"FDA menthol cigarette ban or severe nicotine reduction mandate\",\"Accelerated cigarette volume decline beyond pricing power offset\",\"State and federal excise tax hikes compressing margins\",\"Illicit market growth undermining legal cigarette volumes\",\"NJOY commercialization fails to achieve scale or profitability\",\"Rising interest rates pressuring high-yield equity valuations\"],\"assumptions\":{\"revenue_cagr_3y\":-0.005,\"ebit_margin_target\":0.44,\"wacc\":0.075,\"terminal_multiple\":11.5},\"scenarios\":{\"bear\":{\"target_price\":58.0,\"prob\":0.2,\"notes\":\"Regulatory crackdown on menthol or accelerated volume decline compresses multiple to ~9x.\"},\"base\":{\"target_price\":73.0,\"prob\":0.55,\"notes\":\"Steady pricing offsets volume decline; NJOY grows modestly; 11-12x forward earnings.\"},\"bull\":{\"target_price\":82.0,\"prob\":0.25,\"notes\":\"Smoke-free portfolio accelerates; multiple re-rates to 13x on improved growth profile.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward EPS ~$6.50 (normalized vs depressed TTM of $4.12 impacted by one-time charges). Applied 11-12x forward P/E for base case reflecting mature tobacco cash-flow profile. TTM EPS YoY -37% appears driven by non-recurring items; forward P/E 10.3x confirms street sees normalization. ~9.3% price upside to 12M target plus 7.2% dividend supports BUY. Confidence moderate due to regulatory uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "FDA menthol cigarette ban or severe nicotine reduction mandate", "Accelerated cigarette volume decline beyond pricing power offset", "State and federal excise tax hikes compressing margins", "Illicit market growth undermining legal cigarette volumes", "NJOY commercialization fails to achieve scale or profitability", "Rising interest rates pressuring high-yield equity valuations" ], "ticker": "MO", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady pricing offsets volume decline; NJOY grows modestly; 11-12x forward earnings.", "target_price": 73 }, "bear": { "prob": 0.2, "notes": "Regulatory crackdown on menthol or accelerated volume decline compresses multiple to ~9x.", "target_price": 58 }, "bull": { "prob": 0.25, "notes": "Smoke-free portfolio accelerates; multiple re-rates to 13x on improved growth profile.", "target_price": 82 } }, "confidence": 0.62, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": -0.005, "terminal_multiple": 11.5, "ebit_margin_target": 0.44 }, "key_drivers": [ { "driver": "Cigarette pricing power offsetting volume declines", "impact": "HIGH", "direction": "POS" }, { "driver": "NJOY and smoke-free product portfolio growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Secular decline in combustible cigarette volumes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share repurchase program reducing share count", "impact": "MED", "direction": "POS" }, { "driver": "High dividend yield attracting income-focused capital", "impact": "MED", "direction": "POS" }, { "driver": "FDA regulatory actions on menthol and nicotine levels", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated leverage with negative book equity", "impact": "MED", "direction": "NEG" }, { "driver": "Low beta providing portfolio defensiveness", "impact": "LOW", "direction": "POS" }, { "driver": "Potential excise tax increases", "impact": "MED", "direction": "NEG" } ], "method_notes": "Earnings-power valuation anchored on forward EPS ~$6.50 (normalized vs depressed TTM of $4.12 impacted by one-time charges). Applied 11-12x forward P/E for base case reflecting mature tobacco cash-flow profile. TTM EPS YoY -37% appears driven by non-recurring items; forward P/E 10.3x confirms street sees normalization. ~9.3% price upside to 12M target plus 7.2% dividend supports BUY. Confidence moderate due to regulatory uncertainty. Not investment advice.", "current_price": 66.8, "recommendation": "BUY", "thesis_bullets": [ "~7.2% dividend yield provides strong downside support and total return floor", "Forward P/E of ~10.3x implies normalized EPS well above depressed TTM figure", "Pricing power consistently offsets mid-single-digit cigarette volume declines", "NJOY acquisition positions Altria in growing reduced-risk product category", "Massive FCF (~$8.9B TTM) funds dividends, buybacks, and debt reduction" ], "target_price_6m": 70.5, "target_price_12m": 73 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 39407, "createdAt": "2026-04-09T05:21:24.890Z", "usage": { "inputTokens": 3577, "outputTokens": 1756, "costUsd": 0.061785 } }, { "id": "cmnr14lnj0557p6581h1r55qs", "runId": "cmnr14lng0552p658gprm25ij", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst v1.0\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MO\",\n \"currency\": \"USD\",\n \"current_price\": 66.8,\n \"target_price_6m\": 68.0,\n \"target_price_12m\": 70.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"Stable high dividend yield supports income.\", \"Declining cigarette volumes pressure growth.\", \"Regulatory risks remain elevated in tobacco.\", \"Strong cash flow enables shareholder returns.\", \"Valuation near fair value with mixed outlook.\"],\n \"key_drivers\": [\n { \"driver\": \"Dividend yield and policy\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Cigarette volume decline trend\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory and taxation changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Cost efficiency and margin management\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Growth in alternative products\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt levels and financial leverage\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Market share stability in core segments\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\"Accelerated decline in smoking rates\", \"Increased government regulation or litigation\", \"Competition from non-combustible alternatives\", \"Economic downturn affecting consumer spending\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": -0.02,\n \"ebit_margin_target\": 0.40,\n \"wacc\": 0.07,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 60.0, \"prob\": 0.3, \"notes\": \"Severe volume decline and regulatory hits.\" },\n \"base\": { \"target_price\": 70.0, \"prob\": 0.5, \"notes\": \"Steady decline with stable dividends.\" },\n \"bull\": { \"target_price\": 75.0, \"prob\": 0.2, \"notes\": \"Better alternative product sales growth.\" }\n },\n \"method_notes\": \"DCF with declining growth assumptions. HOLD as expected return ~5% with mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Analyst v1.0", "risks": [ "Accelerated decline in smoking rates", "Increased government regulation or litigation", "Competition from non-combustible alternatives", "Economic downturn affecting consumer spending" ], "ticker": "MO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady decline with stable dividends.", "target_price": 70 }, "bear": { "prob": 0.3, "notes": "Severe volume decline and regulatory hits.", "target_price": 60 }, "bull": { "prob": 0.2, "notes": "Better alternative product sales growth.", "target_price": 75 } }, "confidence": 0.6, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": -0.02, "terminal_multiple": 10, "ebit_margin_target": 0.4 }, "key_drivers": [ { "driver": "Dividend yield and policy", "impact": "HIGH", "direction": "POS" }, { "driver": "Cigarette volume decline trend", "impact": "HIGH", "direction": "NEG" }, { "driver": "Regulatory and taxation changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost efficiency and margin management", "impact": "MED", "direction": "POS" }, { "driver": "Growth in alternative products", "impact": "MED", "direction": "POS" }, { "driver": "Debt levels and financial leverage", "impact": "LOW", "direction": "NEG" }, { "driver": "Market share stability in core segments", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF with declining growth assumptions. HOLD as expected return ~5% with mixed evidence. Not investment advice.", "current_price": 66.8, "recommendation": "HOLD", "thesis_bullets": [ "Stable high dividend yield supports income.", "Declining cigarette volumes pressure growth.", "Regulatory risks remain elevated in tobacco.", "Strong cash flow enables shareholder returns.", "Valuation near fair value with mixed outlook." ], "target_price_6m": 68, "target_price_12m": 70 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 346, "createdAt": "2026-04-09T05:21:24.890Z", "usage": { "inputTokens": 2092, "outputTokens": 3149, "costUsd": 0.001908 } }, { "id": "cmnr14lnj0555p658kfivt9ax", "runId": "cmnr14lng0552p658gprm25ij", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\"model\":\"Altria Equity Research Model\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MO\",\"currency\":\"USD\",\"current_price\":66.8,\"target_price_6m\":68.5,\"target_price_12m\":70.0,\"recommendation\":\"HOLD\",\"confidence\":0.75,\"thesis_bullets\":[\"High 7.2% dividend yield provides a strong valuation floor for income-oriented investors.\",\"Dominant Marlboro market share enables pricing power to offset secular cigarette volume declines.\",\"Successful NJOY expansion and oral nicotine growth are vital for long-term sustainability.\",\"Significant debt load and regulatory headwinds limit potential for meaningful P/E multiple expansion.\",\"Current price near 52-week highs suggests limited capital appreciation upside from here.\"],\"key_drivers\":[{\"driver\":\"Cigarette volume decline rates\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"NJOY retail share growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pricing power effectiveness\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"FDA regulatory actions\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Interest rate environment\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Share repurchase program\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Accelerated decline in traditional cigarette volumes.\",\"Increased competition in the e-vapor and oral nicotine segments.\",\"Adverse litigation outcomes or federal excise tax hikes.\"],\"assumptions\":{\"revenue_cagr_3y\":0.01,\"ebit_margin_target\":0.43,\"wacc\":0.075,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":58.0,\"prob\":0.2,\"notes\":\"Accelerated volume declines and regulatory setbacks.\"},\"base\":{\"target_price\":70.0,\"prob\":0.6,\"notes\":\"Steady pricing power and moderate smoke-free growth.\"},\"bull\":{\"target_price\":78.0,\"prob\":0.2,\"notes\":\"Faster NJOY adoption and favorable regulatory environment.\"}},\"method_notes\":\"Valuation based on 10.5x forward P/E and DCF. HOLD reflects limited price upside despite strong yield. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Altria Equity Research Model", "risks": [ "Accelerated decline in traditional cigarette volumes.", "Increased competition in the e-vapor and oral nicotine segments.", "Adverse litigation outcomes or federal excise tax hikes." ], "ticker": "MO", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady pricing power and moderate smoke-free growth.", "target_price": 70 }, "bear": { "prob": 0.2, "notes": "Accelerated volume declines and regulatory setbacks.", "target_price": 58 }, "bull": { "prob": 0.2, "notes": "Faster NJOY adoption and favorable regulatory environment.", "target_price": 78 } }, "confidence": 0.75, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.01, "terminal_multiple": 10.5, "ebit_margin_target": 0.43 }, "key_drivers": [ { "driver": "Cigarette volume decline rates", "impact": "HIGH", "direction": "NEG" }, { "driver": "NJOY retail share growth", "impact": "MED", "direction": "POS" }, { "driver": "Pricing power effectiveness", "impact": "HIGH", "direction": "POS" }, { "driver": "FDA regulatory actions", "impact": "HIGH", "direction": "NEG" }, { "driver": "Interest rate environment", "impact": "MED", "direction": "NEG" }, { "driver": "Share repurchase program", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on 10.5x forward P/E and DCF. HOLD reflects limited price upside despite strong yield. Not investment advice.", "current_price": 66.8, "recommendation": "HOLD", "thesis_bullets": [ "High 7.2% dividend yield provides a strong valuation floor for income-oriented investors.", "Dominant Marlboro market share enables pricing power to offset secular cigarette volume declines.", "Successful NJOY expansion and oral nicotine growth are vital for long-term sustainability.", "Significant debt load and regulatory headwinds limit potential for meaningful P/E multiple expansion.", "Current price near 52-week highs suggests limited capital appreciation upside from here." ], "target_price_6m": 68.5, "target_price_12m": 70 }, "errorsJson": { "attempts": [ { "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).", "attempt": 0, "rawOutputTruncated": "{\"model\":\"Altria Valuation Model v1.0\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MO\",\"currency\":\"USD\",\"current_price\":66.8,\"target_price_6m\":68.5,\"target_price_12m\":70.0,\"recommendation\":\"HOLD\",\"confidence\":0.7,\"thesis_bullets\":[\"Robust 7.2% dividend yield provides a strong valuation floor for income-focused investors.\",\"Dominant 40%+ market share in US cigarettes enables significant pricing power to offset volumes.\",\"NJOY integration and expansion into smoke-free categories are critical for long-term terminal value.\",\"High debt-to-equity and secular industry decline limit significant P/E multiple expansion potential.\",\"Current valuation near 52-week highs suggests limited near-term upside without major catalysts.\"],\"key_drivers\":[{\"driver\":\"NJOY market share gains\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Marlboro volume attrition\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Federal excise tax changes\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"ABI stake monetization\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"" } ], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 21384, "createdAt": "2026-04-09T05:21:24.890Z", "usage": { "inputTokens": 2777, "outputTokens": 488, "costUsd": 0.01141 } }, { "id": "cmnr14lnj0553p6581042k4tb", "runId": "cmnr14lng0552p658gprm25ij", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MO\",\"currency\":\"USD\",\"current_price\":66.8,\"target_price_6m\":68.4,\"target_price_12m\":69.5,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Combustible pricing offsets volume declines, sustaining high operating margins.\",\"Dividend yield above 7% supports total return and downside protection.\",\"Low-beta cash generation appeals in uncertain macro and rate markets.\",\"Revenue and EPS declines reflect secular cigarette pressure and limited growth.\",\"Leverage, regulation, and reduced-risk execution cap multiple expansion.\"],\"key_drivers\":[{\"driver\":\"Cigarette price realization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Industry shipment declines\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield support\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"NJOY and oral nicotine scale\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FDA menthol/nicotine actions\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Debt paydown and buybacks\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Excise tax and litigation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Consumer resilience in premium brands\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Accelerated cigarette volume declines\",\"Adverse FDA rulings on menthol or nicotine levels\",\"NJOY integration or authorization setbacks\",\"Higher litigation, settlement, or excise tax costs\",\"Refinancing or rate pressure on income-stock valuation\"],\"assumptions\":{\"revenue_cagr_3y\":-0.01,\"ebit_margin_target\":0.43,\"wacc\":0.08,\"terminal_multiple\":11},\"scenarios\":{\"bear\":{\"target_price\":58,\"prob\":0.3,\"notes\":\"Faster volume erosion and tougher FDA actions compress the multiple.\"},\"base\":{\"target_price\":69.5,\"prob\":0.5,\"notes\":\"Pricing, cash flow, and dividend support offset secular declines.\"},\"bull\":{\"target_price\":78,\"prob\":0.2,\"notes\":\"Reduced-risk gains and stable volumes drive modest rerating.\"}},\"method_notes\":\"Blended 12M valuation using normalized earnings multiple and EV/EBITDA cross-check, anchored by dividend support and modest deleveraging. Snapshot quote/fundamental fields were kept authoritative; no sell-side price targets used. HOLD matches only ~4% price upside versus material regulatory and volume risks; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Accelerated cigarette volume declines", "Adverse FDA rulings on menthol or nicotine levels", "NJOY integration or authorization setbacks", "Higher litigation, settlement, or excise tax costs", "Refinancing or rate pressure on income-stock valuation" ], "ticker": "MO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Pricing, cash flow, and dividend support offset secular declines.", "target_price": 69.5 }, "bear": { "prob": 0.3, "notes": "Faster volume erosion and tougher FDA actions compress the multiple.", "target_price": 58 }, "bull": { "prob": 0.2, "notes": "Reduced-risk gains and stable volumes drive modest rerating.", "target_price": 78 } }, "confidence": 0.63, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": -0.01, "terminal_multiple": 11, "ebit_margin_target": 0.43 }, "key_drivers": [ { "driver": "Cigarette price realization", "impact": "HIGH", "direction": "POS" }, { "driver": "Industry shipment declines", "impact": "HIGH", "direction": "NEG" }, { "driver": "Dividend yield support", "impact": "MED", "direction": "POS" }, { "driver": "NJOY and oral nicotine scale", "impact": "MED", "direction": "POS" }, { "driver": "FDA menthol/nicotine actions", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt paydown and buybacks", "impact": "MED", "direction": "POS" }, { "driver": "Excise tax and litigation", "impact": "MED", "direction": "NEG" }, { "driver": "Consumer resilience in premium brands", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended 12M valuation using normalized earnings multiple and EV/EBITDA cross-check, anchored by dividend support and modest deleveraging. Snapshot quote/fundamental fields were kept authoritative; no sell-side price targets used. HOLD matches only ~4% price upside versus material regulatory and volume risks; not investment advice.", "current_price": 66.8, "recommendation": "HOLD", "thesis_bullets": [ "Combustible pricing offsets volume declines, sustaining high operating margins.", "Dividend yield above 7% supports total return and downside protection.", "Low-beta cash generation appeals in uncertain macro and rate markets.", "Revenue and EPS declines reflect secular cigarette pressure and limited growth.", "Leverage, regulation, and reduced-risk execution cap multiple expansion." ], "target_price_6m": 68.4, "target_price_12m": 69.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_080a935effd720ec0069d75b6268f0819789fdca44f35b5333", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 46320, "createdAt": "2026-04-09T05:21:24.890Z", "usage": { "inputTokens": 2361, "outputTokens": 2476, "costUsd": 0.038796 } }, { "id": "cmnr14lnj0556p658wcbbrvqt", "runId": "cmnr14lng0552p658gprm25ij", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"MO\",\n \"currency\": \"USD\",\n \"current_price\": 66.8,\n \"target_price_6m\": 70.5,\n \"target_price_12m\": 75,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"7.2% dividend yield supported by robust FCF\",\n \"Pricing power offsets ongoing cigarette declines\",\n \"Undervalued at 10.3x forward P/E\",\n \"Regulatory and litigation risks limit upside\",\n \"Smoke-free pivot offers future growth potential\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"High dividend yield sustainability\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cigarette volume erosion\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Tobacco pricing power\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory pressures\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Smoke-free category growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Balance sheet leverage\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Share repurchase capacity\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Stricter anti-tobacco regulations\",\n \"Ongoing litigation settlements\",\n \"Accelerated volume declines\",\n \"Competition in nicotine alternatives\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": -0.02,\n \"ebit_margin_target\": 0.42,\n \"wacc\": 0.085,\n \"terminal_multiple\": 12.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 58,\n \"prob\": 0.3,\n \"notes\": \"Accelerated regulations drive faster volume drops.\"\n },\n \"base\": {\n \"target_price\": 75,\n \"prob\": 0.45,\n \"notes\": \"Pricing offsets modest declines and sustains payout.\"\n },\n \"bull\": {\n \"target_price\": 88,\n \"prob\": 0.25,\n \"notes\": \"Strong smoke-free growth accelerates revenue.\"\n }\n },\n \"method_notes\": \"Dividend discount + EV/EBITDA terminal. 12M target implies 12% appreciation plus ~7% yield for BUY. Snapshot data used as baseline. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Stricter anti-tobacco regulations", "Ongoing litigation settlements", "Accelerated volume declines", "Competition in nicotine alternatives" ], "ticker": "MO", "currency": "USD", "scenarios": { "base": { "prob": 0.45, "notes": "Pricing offsets modest declines and sustains payout.", "target_price": 75 }, "bear": { "prob": 0.3, "notes": "Accelerated regulations drive faster volume drops.", "target_price": 58 }, "bull": { "prob": 0.25, "notes": "Strong smoke-free growth accelerates revenue.", "target_price": 88 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": -0.02, "terminal_multiple": 12.5, "ebit_margin_target": 0.42 }, "key_drivers": [ { "driver": "High dividend yield sustainability", "impact": "HIGH", "direction": "POS" }, { "driver": "Cigarette volume erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Tobacco pricing power", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory pressures", "impact": "HIGH", "direction": "NEG" }, { "driver": "Smoke-free category growth", "impact": "MED", "direction": "POS" }, { "driver": "Balance sheet leverage", "impact": "MED", "direction": "NEG" }, { "driver": "Share repurchase capacity", "impact": "MED", "direction": "POS" } ], "method_notes": "Dividend discount + EV/EBITDA terminal. 12M target implies 12% appreciation plus ~7% yield for BUY. Snapshot data used as baseline. Not investment advice.", "current_price": 66.8, "recommendation": "BUY", "thesis_bullets": [ "7.2% dividend yield supported by robust FCF", "Pricing power offsets ongoing cigarette declines", "Undervalued at 10.3x forward P/E", "Regulatory and litigation risks limit upside", "Smoke-free pivot offers future growth potential" ], "target_price_6m": 70.5, "target_price_12m": 75 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "8b82c63d-943d-9363-a13c-52c242551d60", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 12873, "createdAt": "2026-04-09T05:21:24.890Z", "usage": { "inputTokens": 2701, "outputTokens": 2775, "costUsd": 0.049728 } } ] } }